Skip Nav Destination
POD24 in MZL: a means to an end or an end point in itself?
Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study
Issue Archive
Table of Contents
BLOOD COMMENTARIES
CLINICAL TRIALS AND OBSERVATIONS
POD24 in MZL: a means to an end or an end point in itself?
Clinical Trials & Observations
BLOOD SPOTLIGHT
CLINICAL TRIALS AND OBSERVATIONS
Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study
Clinical Trials & Observations
Brief Report
Stefano Luminari,Michele Merli,Sara Rattotti,Vittoria Tarantino,Luigi Marcheselli,Federica Cavallo,Marzia Varettoni,Benedetta Bianchi,Francesco Merli,Alessandra Tedeschi,Giuseppina Cabras,Francesca Re,Carlo Visco,Marcia Torresan Delamain,Emanuele Cencini,Michele Spina,Simone Ferrero,Angela Ferrari,Marina Deodato,Donato Mannina,Ombretta Annibali,Angela Rago,Lorella Orsucci,Irene Defrancesco,Marco Frigeni,Marina Cesaretti,Luca Arcaini
LYMPHOID NEOPLASIA
Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma
Anja Mottok,Stacy S. Hung,Elizabeth A. Chavez,Bruce Woolcock,Adèle Telenius,Lauren C. Chong,Barbara Meissner,Hisae Nakamura,Christopher Rushton,Elena Viganò,Clementine Sarkozy,Randy D. Gascoyne,Joseph M. Connors,Susana Ben-Neriah,Andrew Mungall,Marco A. Marra,Reiner Siebert,David W. Scott,Kerry J. Savage,Christian Steidl
MYELOID NEOPLASIA
Increased SLAMF7high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab
Takaaki Maekawa,Shoichiro Kato,Toshikuni Kawamura,Kohei Takada,Takehiro Sone,Hiraku Ogata,Keita Saito,Takuya Izumi,Shigeki Nagao,Kosuke Takano,Yosuke Okada,Noriaki Tachi,Masahiro Teramoto,Toshikatsu Horiuchi,Reina Hikota-Saga,Kaori Endo-Umeda,Shigeyuki Uno,Yukiko Osawa,Ayako Kobayashi,Shinichi Kobayashi,Ken Sato,Michihiro Hashimoto,Shinya Suzu,Kensuke Usuki,Soji Morishita,Marito Araki,Makoto Makishima,Norio Komatsu,Fumihiko Kimura
PLATELETS AND THROMBOPOIESIS
LETTER TO BLOOD
Hierarchy of mono- and biallelic TP53 alterations in multiple myeloma cell fitness
Umair Munawar,Leo Rasche,Nicole Müller,Cornelia Vogt,Matteo Da-Via,Larissa Haertle,Panagiota Arampatzi,Sascha Dietrich,Markus Roth,Andoni Garitano-Trojaola,Maximilian Johannes Steinhardt,Susanne Strifler,Miguel Gallardo,Joaquin Martinez-Lopez,Ralf C. Bargou,Tobias Heckel,Hermann Einsele,Thorsten Stühmer,K. Martin Kortüm,Santiago Barrio
BLOOD WORK
ERRATUM
-
Cover Image
Cover Image
Silver-stained femur bone marrow section from a romiplostim-treated humanized NOG mouse. Elotuzumab ameliorated myelofibrosis induced by romiplostim administration. See the article by Maekawa et al on page 814.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals